FDA Issues Draft Guidance on Genome Editing Safety Assessment Using NGS

The U.S. Food and Drug Administration (FDA) has released a new draft guidance titled “Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing”, marking an important step forward in the regulatory framework for genome editing therapies.

This guidance provides detailed recommendations for sponsors developing genome editing-based gene therapies, with a strong focus on the use of next-generation sequencing (NGS) to evaluate safety risks such as off-target editing and genomic instability. It applies to both ex vivo and in vivo genome editing approaches and is intended to support regulatory submissions, including INDs and BLAs.

A Clearer Regulatory Path for Genome Editing Therapies

Genome editing technologies, including CRISPR/Cas, TALENs, and other emerging platforms, offer significant potential to treat genetic diseases. However, unintended edits to the genome remain a key safety concern.

The FDA’s draft guidance introduces a more standardized and science-driven framework for assessing these risks, including:

• Comprehensive off-target analysis using NGS and bioinformatics
• On-target editing assessment to quantify intended and unintended edits
• Chromosomal integrity evaluation, including translocations and large genomic changes
• Integration of in silico, biochemical, and cell-based approaches for off-target site identification
• Consideration of human genetic variation in off-target risk assessment

Importantly, the FDA emphasizes that sponsors should use multiple complementary approaches and ensure that assays are sensitive enough to detect low-frequency editing events.

NGS at the Center of Safety Evaluation

A central theme of the guidance is the critical role of NGS in enabling comprehensive safety assessment. Sponsors are encouraged to:

• Select appropriate sequencing strategies (short-read vs. long-read) based on edit type
• Ensure sufficient sequencing depth and sensitivity to detect rare events
• Provide detailed bioinformatics workflows, parameters, and reporting formats
• Submit tabulated datasets and metadata to support regulatory review

These expectations reinforce the growing importance of robust NGS capabilities in gene therapy development programs.

Early Engagement with FDA Encouraged

The FDA also highlights the importance of early interaction with the agency through programs such as INTERACT and pre-IND meetings. This collaborative approach is intended to streamline development and reduce regulatory uncertainty, particularly for innovative and individualized therapies.

What This Means for Sponsors

This draft guidance signals a continued shift toward data-driven, standardized safety evaluation for genome editing therapies. For sponsors, this means:

• Greater clarity on regulatory expectations
• Increased emphasis on NGS assay design, validation, and reporting
• A need for integrated strategies combining experimental and computational methods
• Earlier and more proactive engagement with regulatory authorities

Avance Biosciences Perspective

At Avance Biosciences, we see this guidance as highly aligned with the direction of the field. The FDA’s emphasis on NGS-based safety assessment, bioinformatics rigor, and comprehensive off-target analysis reflects the capabilities required to support modern gene therapy development.

Our experience with NGS, including short-read and long-read sequencing platforms, along with bioinformatics-driven analysis workflows, positions us to help sponsors design and execute studies that meet these evolving regulatory expectations.

References

• FDA Announcement – FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development
• FDA Draft Guidance – Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing